Patents by Inventor Bettina Husen
Bettina Husen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8435973Abstract: Substituted steroid compounds which represent selective inhibitors of 17?-hydroxysteroid dehydrogenase type I (17?-HSD1) and, in addition, which may represent inhibitors of the steroid sulfatase, salts thereof, pharmaceutical preparations containing these compounds, and a process for the preparation of these compounds. Also disclosed is a therapeutic method of using such substituted steroid compounds, particularly in the treatment, inhibition, prophylaxis or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of 17?-hydroxysteroid dehydrogenase type I and/or steroid sulfatase enzymes and/or requiring lowering of the endogenous 17?-estradiol concentration.Type: GrantFiled: September 28, 2010Date of Patent: May 7, 2013Assignee: Abbott Products GmbHInventors: Josef Messinger, Heinrich-Hubert Thole, Bettina Husen, Michael Weske, Pasi Koskimies, Lila Pirkkala
-
Patent number: 8288367Abstract: Substituted estratriene compounds of formula (I) useful in therapy, especially in the treatment or inhibition of a steroid hormone dependent disorder requiring the inhibition of a 17?-hydroxysteroid dehydrogenase (17?-HSD) type 1, type 2 and/or type 3 enzyme, as well as their salts, pharmaceutical compositions containing such compounds and processes for preparing such compounds.Type: GrantFiled: November 29, 2007Date of Patent: October 16, 2012Assignee: Solvay Pharmaceuticals GmBHInventors: Josef Messinger, Uwe Schoen, Heinrich-Hubert Thole, Bettina Husen, Pasi Koskimies, Mikko Unkila
-
Patent number: 8088758Abstract: 3,15-substituted estrone compounds which act as inhibitors of 17?-hydroxysteroid dehydrogenase type I (17?-HSD1), salts thereof, pharmaceutical preparations containing such compounds, processes for preparing such compounds, and therapeutic uses of such compounds, particularly in the treatment or inhibition of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of 17?-hydroxysteroid dehydrogenase type I enzymes and/or requiring the lowering of the endogenous 17?-estradiol concentration, as well as the general use of selective 17?-hydroxysteroid dehydrogenase type 1 inhibitors which possess in addition no or only pure antagonistic binding affinities to the estrogen receptor for the treatment or inhibition of benign gynecological disorders, particularly endometriosis.Type: GrantFiled: November 9, 2004Date of Patent: January 3, 2012Assignee: Abbott Products GmbHInventors: Josef Messinger, Heinrich-Hubert Thole, Bettina Husen, Bartholomeus Johannes Van Steen, Gyula Schneider, Johannes Bernardus Everardus Hulshof, Pasi Koskimies, Nina Johansson, Jerzy Adamski
-
Patent number: 8080540Abstract: Estratrien-triazoles corresponding to formula (I) (shown below) which are useful in therapy, especially for the treatment and/or prevention or inhibition of a steroid hormone dependent disorder, preferably a steroid hormone dependent disease or disorder requiring the inhibition of a 17?-hydroxysteroid dehydrogenase (17?-HSD) such as 17?-HSD type 1, type 2 or type 3 enzyme.Type: GrantFiled: September 18, 2007Date of Patent: December 20, 2011Assignee: Abbott Products GmbHInventors: Josef Messinger, Uwe Schoen, Heinrich-Hubert Thole, Bettina Husen, Pasi Koskimies, Lila Kallio nee Pirkkala
-
Patent number: 8030298Abstract: The present invention relates to novel substituted steroid derivatives which represent selective inhibitors of the 17?-hydroxysteroid dehydrogenase type I (17?-HSD1) and, in addition, which may represent inhibitors of the steroid sulphatase, as well as to their salts, to pharmaceutical preparations containing these compounds and to processes for the preparation of these compounds. Furthermore, the invention concerns the therapeutic use of said novel substituted steroid derivatives, particularly their use in the treatment, inhibition, prophylaxis or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of 17?-hydroxysteroid dehydrogenase type I and/or steroid sulphatase enzymes and/or requiring the lowering of the endogenous 17?-estradiol concentration.Type: GrantFiled: May 26, 2006Date of Patent: October 4, 2011Assignee: Abbott Products GmbHInventors: Josef Messinger, Heinrich-Hubert Thole, Bettina Husen, Michael Weske, Pasi Koskimies, Lila Pirkkala
-
Publication number: 20110021480Abstract: Substituted steroid compounds which represent selective inhibitors of 17?-hydroxysteroid dehydrogenase type I (17?-HSD1) and, in addition, which may represent inhibitors of the steroid sulfatase, salts thereof, pharmaceutical preparations containing these compounds, and a process for the preparation of these compounds. Also disclosed is a therapeutic method of using such substituted steroid compounds, particularly in the treatment, inhibition, prophylaxis or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of 17?-hydroxysteroid dehydrogenase type I and/or steroid sulfatase enzymes and/or requiring lowering of the endogenous 17?-estradiol concentration.Type: ApplicationFiled: September 28, 2010Publication date: January 27, 2011Applicant: Solvay Pharmaceuticals GmbHInventors: Josef Messinger, Heinrich-Hubert Thole, Bettina Husen, Michael Weske, Pasi Koskimies, Lila Pirkkala
-
Patent number: 7524853Abstract: Thiophenepyrimidinone compounds and their use in therapy, especially for use in the treatment and/or prevention of a steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring inhibition of 17?-hydroxysteroid dehydrogenase enzymes.Type: GrantFiled: December 15, 2004Date of Patent: April 28, 2009Assignees: Solvay Pharmaceuticals B.V., Solvay Pharmaceuticals GmbHInventors: Leena Hirvelae, Nina Johansson, Pasi Koskimies, Olli Taneli Pentikaeinen, Tommi Nyroenen, Tiina Annamaria Salminen, Mark Stuart Johnson, Pekka Lehtovuori, Pauli Saarenketo, Bartholomeus Johannes Van Steen, Heinrich-Hubert Thole, Mikko Unkila, Josef Messinger, Johanna Kiviniemi, Lila Pirkkala, Bettina Husen
-
Publication number: 20080255075Abstract: Substituted estratriene compounds of formula (I) useful in therapy, especially in the treatment or inhibition of a steroid hormone dependent disorder requiring the inhibition of a 17?-hydroxysteroid dehydrogenase (17?-HSD) type 1, type 2 and/or type 3 enzyme, as well as their salts, pharmaceutical compositions containing such compounds and processes for preparing such compounds.Type: ApplicationFiled: November 29, 2007Publication date: October 16, 2008Applicant: Solvay Pharmaceuticals GmbHInventors: Josef MESSINGER, Uwe Schoen, Heinrich-Hubert Thole, Bettina Husen, Pasi Koskimies, Mikko Unkila
-
Publication number: 20080249075Abstract: Retrosteroidal compounds corresponding to formula I, representing progesterone receptor modulators, and their production, and pharmaceutical preparations containing these compounds. These compounds are useful in the treatment of benign gynecological disorders such as endometriosis and uterine fibroids, as well as for female birth control and for hormone replacement therapy.Type: ApplicationFiled: March 20, 2008Publication date: October 9, 2008Applicant: Solvay Pharmaceuticals GmbHInventors: Josef Messinger, Christiane Boecker, Heinrich-Hubert Thole, Bettina Husen, Maria Hinaje, Monika Buchholz
-
Publication number: 20080146531Abstract: Estratrien-triazoles corresponding to formula (I) (shown below) which are useful in therapy, especially for the treatment and/or prevention or inhibition of a steroid hormone dependent disorder, preferably a steroid hormone dependent disease or disorder requiring the inhibition of a 17?-hydroxysteroid dehydrogenase (17?-HSD) such as 17?-HSD type 1, type 2 or type 3 enzyme.Type: ApplicationFiled: September 18, 2007Publication date: June 19, 2008Applicant: SOLVAY PHARMACEUTICALS GmbHInventors: Josef Messinger, Uwe Schoen, Heinrich-Hubert Thole, Bettina Husen, Pasi Koskimies, Lila KALLIO nee Pirkkala
-
Publication number: 20070082876Abstract: Retrosteroidal compounds of formula I which act as progesterone receptor modulators, a method for their production, and pharmaceutical preparations containing these compounds. These compounds are preferably used for the treatment of benign gynecological disorders such as endometriosis and uterine fibroids, as well as for female birth control and for hormone replacement therapy (HRT).Type: ApplicationFiled: September 29, 2006Publication date: April 12, 2007Applicant: Solvay Pharmaceuticals GmbHInventors: Joseph Messinger, Heinrich-Hubert Thole, Bettina Husen, Christiane Boecker, Maria Hinaje, Monika Buchholz, Christoph Mark, Vibhuti Klingler-Dabral
-
Publication number: 20060281710Abstract: The present invention relates to novel substituted steroid derivatives which represent selectiv inhibitors of the 17?-hydroxysteroid dehydrogenase type I (17?-HSD1) and, in addition, which may represent inhibitors of the steroid sulphatase, as well as to their salts, to pharmaceutical preparations containing these compounds and to processes for the preparation of these compounds. Furthermore, the invention concerns the therapeutic use of said novel substituted steroid derivatives, particularly their use in the treatment, inhibition, prophylaxis or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of 17?-hydroxysteroid dehydrogenase type I and/or steroid sulphatase enzymes and/or requiring the lowering of the endogenous 17?-estradiol concentration.Type: ApplicationFiled: May 26, 2006Publication date: December 14, 2006Inventors: Josef Messinger, Heinrich-Hubert Thole, Bettina Husen, Michael Weske, Pasi Koskimies, Lila Pirkkala
-
Publication number: 20050192263Abstract: 3,15-substituted estrone compounds which act as inhibitors of 17?-hydroxysteroid dehydrogenase type I (17?-HSD1), salts thereof, pharmaceutical preparations containing such compounds, processes for preparing such compounds, and therapeutic uses of such compounds, particularly in the treatment or inhibition of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of 17?-hydroxysteroid dehydrogenase type I enzymes and/or requiring the lowering of the endogenous 17?-estradiol concentration, as well as the general use of selective 17?-hydroxysteroid dehydrogenase type 1 inhibitors which possess in addition no or only pure antagonistic binding affinities to the estrogen receptor for the treatment or inhibition of benign gynecological disorders, particularly endometriosis.Type: ApplicationFiled: November 9, 2004Publication date: September 1, 2005Applicant: Solvay Pharmaceuticals GmbHInventors: Josef Messinger, Heinrich-Hubert Thole, Bettina Husen, Bartholomeus Van Steen, Gyula Schneider, Johannes Bernardus Hulshof, Pasi Koskimies, Nina Johansson, Jerzy Adamski
-
Publication number: 20050176742Abstract: Thiophenepyrimidinone compounds and their use in therapy, especially for use in the treatment and/or prevention of a steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring inhibition of 17?-hydroxysteroid dehydrogenase enzymes.Type: ApplicationFiled: December 15, 2004Publication date: August 11, 2005Applicants: Solvay Pharmaceuticals B.V., Solvay Pharmaceuticals GmbHInventors: Leena Hirvelae, Nina Johansson, Pasi Koskimies, Olli Pentikaeinen, Tommi Nyroenen, Tiina Salminen, Mark Johnson, Pekka Lehtovuori, Pauli Saarenketo, Bartholomeus Van Steen, Heinrich-Hubert Thole, Mikko Unkila, Josef Messinger, Johanna Kiviniemi, Lila Pirkkala, Bettina Husen